Camp4 Therapeutics (CAMP) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing RNA-targeting therapeutics to upregulate gene expression for genetic diseases.

• Proprietary RAP Platform identifies regulatory RNAs to generate antisense oligonucleotide (ASO) candidates for gene upregulation.

• Lead preclinical program targets SYNGAP1-related neurodevelopmental disorders; clinical candidate CMP-001 for urea cycle disorders (UCDs).

• Focus on central nervous system diseases and rare genetic disorders with significant unmet need.

• Strategic shift to prioritize SYNGAP program, with UCD program development paused pending partnerships.

Financial performance and metrics

• As of September 30, 2025, historical net tangible book value was $58.7 million, or $1.25 per share.

• After a $100 million offering at $4.25 per share, as adjusted net tangible book value would be $155.3 million, or $2.21 per share.

• Immediate dilution to new investors estimated at $2.04 per share at the assumed offering price.

• Company has never declared or paid dividends and intends to retain earnings for business operations.

Use of proceeds and capital allocation

• Net proceeds intended primarily for general corporate purposes, including R&D, preclinical and clinical development, commercialization, acquisitions, collaborations, working capital, and capital expenditures.

• Management retains broad discretion over allocation of proceeds; specific amounts for each use not predetermined.

• Pending use, proceeds may be invested in liquid, low-risk instruments for capital preservation.